Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month High – Here’s What Happened

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares changing hands. The stock had previously closed at $52.25.

Analysts Set New Price Targets

A number of analysts have recently commented on RCDTF shares. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research note on Monday, October 7th. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The firm’s fifty day moving average is $52.20 and its 200-day moving average is $52.03. The stock has a market capitalization of $10.78 billion, a PE ratio of 26.13 and a beta of 0.33.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.